Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira

Specialty Injectable sales up 12% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira

4Q Revenues: $1.1 billion (+8%)

4Q Earnings: $5.3 million (loss of $214 million 4Q11)

FY Revenues: $4.1 billion (+1%)

FY Earnings: $44.2 million (loss of $9.4 million FY11)

Comments: Growth in the quarter was driven strong sales of Specialty Injectable Pharmaceutical (SIP) products, up 12% to $696 million, including Precedex globally and oncolytic oxaliplatin in the U.S., as well as higher volumes for certain products in the EMEA region. SIP sales in the Americas were  $539.6 million, up 13%; EMEA sales were $83.3 million, up 14%; APAC sales were flat at $73.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters